Teva launches generic Zyvox in US to treat severe infections.-Pfizer
January2014- Teva Pharmaceutical Industries Ltd. has launched a generic version equivalent to Zyvox (linezolid), an injectable antibiotic for the treatment of severe infections.
Pfizer owns three U.S. patents that protect the antibiotic Zyvox. It is typically used to treat infections caused by Gram-positive bacteria resistant to other antibiotics. Patients with severe conditions can receive it via infusion, or injection, then switch to pills when leaving the hospital. The basic product patent expires in May 2015, but those concerning delivery methods extend further. A patent on the crystalline form that enhances the solubility of the injectable formulation expires in June 2018. Another patent related to tablet formulation expires in 2020.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins